# Social Anxiety Disorder

Diagnose social anxiety disorder by persistent fear of negative evaluation, avoidance, disproportionate anxiety, and functional impairment; screen with Mini-SPIN or quantify severity with SPIN or LSAS. Select disorder-specific CBT first when acceptable, and use an SSRI when pharmacotherapy is preferred or needed.

**Clinical question:** How should clinicians identify, assess, and treat social anxiety disorder in adults and young people?

Updated: 2026-09-15T17:25:53.870229+00:00

## What matters in practice
- Establish that feared social or performance situations provoke anxiety related to scrutiny or embarrassment, lead to avoidance or endurance with marked distress, and cause functional impairment before assigning social anxiety disorder. [1][18]
- Use the 3-item Mini-SPIN for identification; use a validated measure such as SPIN or LSAS to quantify baseline severity and track response. [22]
- Offer disorder-specific CBT delivered by a competent practitioner; CBT has broad evidence of efficacy for social anxiety disorder and is superior to wait-list control in randomized psychotherapy trials. [6][7][21]
- Sertraline has FDA-label evidence for adult social anxiety disorder from two placebo-controlled trials using LSAS and CGI-I response outcomes. [1]
- Assess suicide risk, depression, other anxiety disorders, alcohol or drug misuse, and nicotine dependence because psychiatric comorbidity is common and changes parallel treatment needs. [18][19][22]

## Confirm clinically significant social anxiety and measure severity

Separate pervasive fear of negative evaluation from ordinary shyness, isolated performance anxiety, and another primary psychiatric disorder.

Document the feared situations, anticipated consequence, anxiety response, avoidance pattern, and functional cost. Social anxiety disorder is characterized by marked, persistent fear of social or performance situations involving unfamiliar people or possible scrutiny, with concern about humiliation or embarrassment; exposure almost always provokes anxiety, and patients avoid situations or endure them with intense distress. The fear and anticipatory avoidance must be associated with marked distress or impairment. [1][18]

For efficient case finding, use the 3-item Mini-Social Phobia Inventory (Mini-SPIN). If screening is positive or the history remains suggestive, obtain a structured description of current social anxiety, avoidance, associated problems, and circumstances, then record baseline severity with the Social Phobia Inventory (SPIN) or Liebowitz Social Anxiety Scale (LSAS). Repeat the same instrument during treatment rather than relying solely on a global impression of improvement. [22]

Map the feared situations before treatment selection. A circumscribed performance presentation may center on speaking, eating, drinking, or writing while observed, whereas generalized social anxiety involves multiple interactions such as meeting unfamiliar people, speaking with authority figures, and public activities. This map becomes the exposure hierarchy and identifies occupational, academic, and interpersonal targets for outcome monitoring. [17]
- Record avoided situations and safety behaviors that maintain avoidance; use these as explicit behavioral treatment targets. [1][23]
- Assess educational, occupational, social, and quality-of-life effects, because guideline outcomes include symptoms as well as functional recovery. [19]
- In adolescents, obtain developmentally appropriate information about peer situations, school participation, and family context before choosing individual, group, or digital CBT delivery. [9][23][24]

*Practical assessment framework for suspected social anxiety disorder. [1][18][22]*

| Clinical domain | Finding supporting social anxiety disorder | Immediate next action |
| --- | --- | --- |
| Core fear | Fear of scrutiny, humiliation, or embarrassment in social or performance situations. [1][18] | Elicit the feared prediction and the situations that trigger it. [1][23] |
| Behavioral pattern | Avoidance, or endurance with intense anxiety or distress. [1][18] | List avoided activities and rank them for graduated exposure. [19][23] |
| Clinical significance | Marked distress or impairment attributable to fear and avoidance. [1] | Document work, school, relationship, and participation consequences. [19] |
| Measurement | Positive Mini-SPIN identifies need for fuller assessment; SPIN or LSAS quantifies severity. [22] | Record a baseline SPIN or LSAS and use the same scale to monitor treatment. [22] |

## Identify comorbidity, substance-related avoidance, and suicide risk before treatment

Social anxiety disorder often coexists with conditions that require concurrent management rather than diagnostic exclusion.

Perform a psychiatric comorbidity assessment rather than treating social avoidance as a stand-alone complaint. Among adults with a primary social anxiety disorder diagnosis, approximately four-fifths experience at least one other psychiatric disorder during life; co-occurring anxiety disorders are reported in up to 70%, affective disorders in up to 65%, nicotine dependence in 27%, and substance-use disorder in about 20%. [18]

Ask whether alcohol, sedatives, cannabis, stimulants, or other drugs are being used before social exposure, after events, or to manage anticipatory anxiety. Substance misuse does not preclude treatment for social anxiety disorder. For hazardous alcohol or drug misuse, provide a brief intervention; for harmful or dependent use, consider referral to a specialist alcohol or drug service while maintaining treatment for social anxiety disorder. [19][22]

Assess suicidal ideation, intent, plan, means, protective factors, and acute changes in risk at evaluation and when initiating treatment. For patients assessed as at risk of suicide, arrange weekly review until increased risk resolves; then review every 2 to 4 weeks during the first 3 months of treatment and monthly thereafter, while continuing support for graduated exposure to feared situations. [19]
- When depression is present, measure and treat it concurrently; depression did not worsen CBT outcome for panic and agoraphobia in a multicenter trial, but social anxiety disorder-specific outcome assessment should still remain explicit. [6]
- Determine whether substance use is principally a consequence of social anxiety, because this informs sequencing of the brief intervention, addiction referral, and exposure-based treatment. [19]
- Do not abandon exposure goals because of suicide-risk monitoring; use closer contact and a graded plan rather than unsupported reassurance. [19]

*Comorbidity actions that alter the initial management plan. [18][19][22]*

| Finding | Clinical implication | Action |
| --- | --- | --- |
| Another anxiety disorder or affective disorder | Psychiatric comorbidity is frequent in social anxiety disorder. [18] | Define each active syndrome and track social anxiety with SPIN or LSAS alongside the comorbid condition. [22] |
| Hazardous alcohol or drug use | May function as avoidance or self-medication and should not preclude social anxiety treatment. [19] | Provide a brief alcohol or drug intervention and continue social anxiety treatment. [19][22] |
| Harmful or dependent alcohol or drug use | Requires addiction-focused care in parallel with anxiety treatment. [19][22] | Consider referral to a specialist alcohol or drug misuse service. [19][22] |
| Suicide risk | Requires intensified early follow-up. [19] | Review weekly until increased risk resolves, then every 2 to 4 weeks during the first 3 months and monthly thereafter. [19] |

## Use disorder-specific CBT to reverse avoidance

Match psychotherapy to the patient’s feared situations and maintain exposure work as the behavioral endpoint.

Offer CBT from a competent practitioner using a relevant treatment manual. CBT is supported across anxiety disorders, including social anxiety disorder, and in a multicenter randomized trial both CBT and psychodynamic therapy produced significantly higher response and remission than waiting-list control among adults with social anxiety disorder. [6][7][21][22]

For social anxiety disorder, structure CBT around a patient-specific formulation: feared negative evaluation, self-focused attention, maladaptive interpretations, safety behaviors, and avoidance. Use behavioral experiments and graduated exposure to test feared predictions in the situations identified at intake. Cognitive approaches derived from the Clark and Wells model specifically target processes maintaining social anxiety, and adolescent adaptations should address developmental peer and school contexts. [23]

Group CBT can be appropriate when the treatment plan includes social-skills work, assertiveness, cognitive restructuring, problem-solving, and exposure. Adolescent group CBT formats have reduced social anxiety versus control conditions; choose group treatment only if the patient can engage with the exposure demands rather than using the group setting as a lower-intensity substitute for behavioral change. [9]
- Use the baseline SPIN or LSAS to define measurable targets and repeat it to assess response. [22]
- Continue graduated exposure even when suicide-risk surveillance is required, with a pace matched to clinical stability. [19]
- Digital CBT may improve access, but outcome evidence in youth is heterogeneous: in one guided online adolescent trial, social anxiety did not improve significantly immediately after treatment, although findings suggested possible value for indicated prevention. [10]

### When to consider psychodynamic therapy

Manual-guided psychodynamic therapy is an evidence-based psychotherapy option when disorder-specific CBT is unavailable, unacceptable, or unsuccessful. In the SOPHO-NET multicenter trial, both psychodynamic therapy and CBT were superior to waiting-list control for LSAS-rated response and remission; the cited result does not establish equivalence between the two active treatments. [7]

*Psychotherapy selection for social anxiety disorder. [6][7][9][10][21][23]*

| Option | Use case | Essential treatment target |
| --- | --- | --- |
| Individual disorder-specific CBT | Preferred when exposure can be individualized to the patient’s avoided social and performance situations. [6][21][23] | Behavioral experiments, graduated exposure, and reduction of safety behaviors. [23] |
| Group CBT | Appropriate when structured social-skills, cognitive, and exposure work fits the patient’s goals. [9] | Assertiveness, problem-solving, cognitive restructuring, and exposure. [9] |
| Psychodynamic therapy | Consider when CBT is unavailable, declined, or has not achieved adequate response. [7] | Manual-guided psychotherapy with response and remission monitoring. [7] |
| Guided digital intervention | Consider as an access-oriented adjunct or low-threshold option, particularly for indicated prevention in youth. [10] | Monitor symptoms rather than presuming post-treatment benefit. [10] |

## Use SSRI treatment when medication is selected and monitor with functional targets

Choose medication when the patient prefers pharmacotherapy, cannot access adequate CBT, or requires a combined strategy after shared decision-making.

Sertraline is FDA-labeled for adult social anxiety disorder. Its efficacy was established in two placebo-controlled adult outpatient trials enrolling patients with DSM-IV social anxiety disorder; primary outcomes included LSAS change and CGI-I response, defined as CGI-I score 1 or 2. Use a consistent baseline symptom measure and functional target so that continuation reflects observable benefit rather than medication exposure alone. [1]

Do not infer pediatric medication efficacy from adult sertraline labeling. A trial history cited for children and adolescents includes fluvoxamine in patients aged 6 to 17 years with social phobia, social anxiety disorder, or generalized anxiety disorder, but this excerpt does not provide a pediatric dosing or treatment algorithm. Prioritize developmentally adapted CBT and use specialist-informed medication decisions when pharmacotherapy is being considered for youth. [16][24]

At follow-up, reassess avoidance, social participation, school or work functioning, SPIN or LSAS score, adverse effects, adherence, substance use, and suicide risk. A patient reporting reduced distress but still avoiding the core feared situation has not completed the behavioral target; revise the exposure hierarchy, evaluate psychotherapy engagement, and address comorbid depression or substance use rather than labeling treatment success prematurely. [19][22][23]
- Use LSAS or SPIN serially; LSAS and CGI-I were the outcome measures in adult sertraline studies. [1][22]
- For patients with active suicide risk, follow weekly until risk is no longer elevated, then every 2 to 4 weeks during the first 3 months and monthly thereafter. [19]
- Keep substance-use treatment and social anxiety treatment active in parallel when alcohol or drug use is hazardous, harmful, or dependent. [19][22]

*Medication and monitoring decisions for social anxiety disorder. [1][16][19][22]*

| Decision point | Action | How to monitor |
| --- | --- | --- |
| Adult selects pharmacotherapy | Consider sertraline, which is FDA-labeled for adult social anxiety disorder. [1] | Track LSAS or SPIN, CGI-style global change, avoidance, and functional goals. [1][22] |
| Adolescent requires treatment | Prioritize developmentally adapted CBT; seek specialist-informed medication planning if pharmacotherapy is under consideration. [23][24] | Track school, peer, and family-relevant functioning with symptom severity. [9][23] |
| Hazardous substance use | Provide a brief intervention without withholding social anxiety treatment. [19][22] | Reassess use pattern and whether it is linked to anticipated or completed social exposure. [19] |
| Elevated suicide risk | Increase contact frequency while maintaining a graded exposure plan. [19] | Weekly until increased risk resolves; then every 2 to 4 weeks for 3 months and monthly thereafter. [19] |

## References
1. [PDF] Sertraline Hydrochloride Tablets USP - DailyMed — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=6b532e6a-b040-4a10-a242-fb6d8dfc0852&type=pdf
2. Generalized anxiety disorder - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/120?q=Generalised+anxiety+disorder&amp%3Bc=suggested
3. Frontiers and hotspots in anxiety disorders: A bibliometric analysis ... — www.cell.com — https://www.cell.com/heliyon/fulltext/S2405-8440(24)11732-X
4. Prevention and treatment of social anxiety disorder in adolescents: mixed method randomised controlled trial of the guided online intervention SOPHIE | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-025-10193-w
5. Multi-session CBM-I for social anxiety: examining psychopathology, cognitive, neural, and psychophysiological effects in a randomized controlled trial | Translational Psychiatry — www.nature.com — https://www.nature.com/articles/s41398-026-04122-2
6. Anxiety disorders | Nature Reviews Disease Primers — www.nature.com — https://www.nature.com/articles/nrdp201724
7. The predictive value of cortisol in psychodynamic psychotherapy for social anxiety disorder: Extended results of the SOPHONET-Study | Translational Psychiatry — www.nature.com — https://www.nature.com/articles/s41398-024-02882-3
8. A Comparison of the Efficacy of Clonazepam and Cognitive-Behavioral Group Therapy for the Treatment of Social Phobia - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S088761850000027X
9. Psychological interventions for social anxiety disorder in children and adolescents: A systematic review and network meta-analysis — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0165032724013156
10. Digital Mental Health Interventions for the Prevention and Treatment of Social Anxiety Disorder in Children, Adolescents, and Young Adults: Systematic Review and Meta-Analysis of Randomized Controlled Trials — www.sciencedirect.com — https://www.sciencedirect.com/org/science/article/pii/S1438887125008167
11. Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0887618507000205
12. Depressive and anxiety disorders linked to... : Medicine - Ovid — journals.lww.com — https://journals.lww.com/md-journal/fulltext/2025/11140/depressive_and_anxiety_disorders_linked_to.140.aspx
13. Treatment of Anxiety Disorders - Oxford Academic — academic.oup.com — https://academic.oup.com/book/61856/chapter/547117580
14. Fluvoxamine CR in the long-term treatment of social ... — academic.oup.com — https://academic.oup.com/ijnp/article-pdf/6/4/317/1994747/6-4-317.pdf
15. The evidence-based pharmacotherapy of social anxiety disorder — academic.oup.com — https://academic.oup.com/ijnp/article/16/1/235/629354
16. 10 Treatment of Anxiety Disorders - Oxford Academic — academic.oup.com — https://academic.oup.com/book/38543/chapter/333672174
17. [PDF] Social anxiety disorder - NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/cg159/documents/social-anxiety-disorder-final-scope2
18. SOCIAL ANXIETY DISORDER - Social Anxiety Disorder - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK327674
19. Social anxiety disorder: recognition, assessment and ... — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/n/nicecg159guid/pdf
20. SCOPE FOR THE DEVELOPMENT OF THE CLINICAL GUIDELINE - Social Anxiety Disorder - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK327659
21. Clinical practice guideline for social anxiety disorder (2021) - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10496046
22. SUMMARY OF RECOMMENDATIONS - Social Anxiety Disorder - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK327653
23. Understanding Social Anxiety Disorder in Adolescents and Improving Treatment Outcomes: Applying the Cognitive Model of Clark and Wells (1995) - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6447508
24. A clinician's quick guide of evidence-based approaches: Childhood anxiety disorders — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4467238

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.